Drug Profile
Research programme: chemotherapeutic adjuvant - AMI Pharm
Alternative Names: AMP-130Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator AMI Pharm
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Unspecified in South Korea
- 22 Feb 2016 Early research in Undefined indication in South Korea (unspecified route)